Byeong-Geon Lee
Chief Executive Officer at GI INNOVATION, INC.
Net worth: - $ as of 2024-03-30
Profile
Byeong-Geon Lee currently works at GI Innovation, Inc., as Chairman & Co-Chief Executive Officer from 2022, Korea Industrial Technology Association, as Vice Chairman, The National Academy of Engineering of Korea, as Director, Genome & Co., as Non-Executive Director, Hapln Science Co. Ltd., as Non-Executive Director, and Creactive Health Co. Ltd., as Non-Executive Director.
Dr. Lee also formerly worked at Green Cross Corp., as Co-President, Co-CEO & Director from 2012 to 2014, Egen, Inc., as President & Chief Executive Officer in 2002, Green Cross Holdings Corp., as President, Co-Chief Executive Officer & Director, ChongKunDang Holdings Corp., as Vice Chairman & Chief Executive Officer, SCM Lifescience Co., Ltd., as Chief Executive Officer, Korea Biotechnology Industry Organization, as Chairman, CoImmune, Inc., as Chairman, Aquavit Pharmaceuticals, Inc., as Director, Duopharma Biotech Bhd., as Independent Non-Executive Director from 2015 to 2017, Stemedica Cell Technologies, Inc., as Director, Genexine, Inc., as Independent Director, Korea Institute of S & T Evalauation & Planning, as Director, LG Chem Ltd., as Head-Drug Development, Samyang Holdings Corp., as Head-Pharmaceutical Division in 1994, the University of Wisconsin, as Research Associate in 1986, and LG Management Development Institute Co., Ltd., as Head-Safety Center in 1987.
Dr. Lee received his doctorate degree from Harvard University, doctorate degree in 1985 from Rice University, and undergraduate degree and graduate degree from Seoul National University.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
GI INNOVATION, INC.
-.--% | 2024-03-31 | 0 ( -.--% ) | - $ | 2024-03-30 |
Byeong-Geon Lee active positions
| Companies | Position | Start |
|---|---|---|
| GENOME & COMPANY | Director/Board Member | - |
| GI INNOVATION, INC. | Chief Executive Officer | 2022-03-03 |
| Creactive Health Co. Ltd. | Director/Board Member | - |
| The National Academy of Engineering of Korea | Director/Board Member | - |
| Korea Industrial Technology Association | Director/Board Member | - |
Hapln Science Co. Ltd.
 Hapln Science Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Hapln Science Co. Ltd. is a drug development company, which focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company was founded on November 22, 2018 and is headquartered in Seongnam, South Korea. | Director/Board Member | - |
Former positions of Byeong-Geon Lee
| Companies | Position | End |
|---|---|---|
CoImmune, Inc.
 CoImmune, Inc. Pharmaceuticals: MajorHealth Technology CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC. | Chairman | 2021-11-14 |
| CHONG KUN DANG HOLDINGS CORP. | Chief Executive Officer | 2018-03-15 |
| GREEN CROSS HOLDINGS CORPORATION | Chief Executive Officer | 2017-02-19 |
| ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░ ░░░░░░░░░ ░░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Training of Byeong-Geon Lee
| Harvard University | Doctorate Degree |
| Rice University | Doctorate Degree |
| Seoul National University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 10 |
|---|---|
| GC BIOPHARMA CORP. | Health Technology |
| LG CHEM, LTD. | Process Industries |
| GREEN CROSS HOLDINGS CORPORATION | Health Technology |
| CHONG KUN DANG HOLDINGS CORP. | Health Technology |
| DUOPHARMA BIOTECH | Health Technology |
| SAMYANG HOLDINGS CORPORATION | Process Industries |
| GENEXINE, INC. | Health Technology |
| SCM LIFESCIENCE CO., LTD. | Health Technology |
| GENOME & COMPANY | Health Technology |
| GI INNOVATION, INC. | Health Technology |
| Private companies | 11 |
|---|---|
Egen, Inc.
 Egen, Inc. Medical SpecialtiesHealth Technology Egen, Inc. operates as a clinical stage biopharmaceutical company which develops novel proprietary nanoparticle delivery technology for therapeutic use. Egen's technology platform is very broad, including polymer, cationic lipid, and molecular biology-based approaches to delivery of nucleic acid and anti-cancer drugs. The primary activities of the company are the application of the TheraPlas and TheraSilence platforms to the treatment of human disease. Egen's lead candidate, EGEN-001, is in Phase II clinical testing for ovarian cancer and in Phase I clinical testing for colorectal cancer. In addition, Egen is pursuing pre-clinical development of its TheraSilence RNAi delivery program for multiple disease applications, as well as other novel disruptive technologies focused on creating the next generation of synthetic nanoparticle delivery systems and nucleic acid-based therapies. It is also active in pursuing partnerships and working with external collaborators to further develop its delivery technology for multiple applications. Egen offers cutting-edge research services relating to non-viral polymeric gene carrier systems, and other approaches for the delivery of nucleic acid and anti-cancer drugs. The company's synthetic biocompatible delivery vehicles can be used to deliver therapeutic genes, inhibitory RNA (RNAi), and small molecules by protecting the therapeutic cargo from degradation, promoting uptake by target cells, and facilitating intracellular trafficking. Egen was founded in 2002 by Sung Wan Kim and is headquartered in Huntsville, AL. | Health Technology |
Aquavit Pharmaceuticals, Inc.
 Aquavit Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aquavit Pharmaceuticals, Inc. operates as a healthcare company that discovers, develops, and commercializes therapeutic products. It offers pharmaceuticals, nutraceuticals, and biologics. The company was founded in October 2010 and is headquartered in New York, NY. | Health Technology |
Stemedica Cell Technologies, Inc.
 Stemedica Cell Technologies, Inc. Pharmaceuticals: MajorHealth Technology Stemedica Cell Technologies, Inc. operates as a biotechnology company that manufactures adult allergenic stem cells. Its adult stem cells which are used by research institutions and hospitals for pre-clinical and clinical studies. It has offices in Mexico, Italy, Switzerland, and France. The company was founded by Roger J. Howe and Maynard A. Howe in 2005 and is headquartered in San Diego, CA. | Health Technology |
| Korea Institute of S & T Evalauation & Planning | |
LG Management Development Institute Co., Ltd.
 LG Management Development Institute Co., Ltd. Miscellaneous Commercial ServicesCommercial Services LG Management Development Institute Co., Ltd. provides management advisory services. The company was founded in 1986 and is headquartered in Kyonggi, South Korea. | Commercial Services |
| The National Academy of Engineering of Korea | |
| Korea Industrial Technology Association | |
| Korea Biotechnology Industry Organization | |
Hapln Science Co. Ltd.
Hapln Science Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Hapln Science Co. Ltd. is a drug development company, which focuses on anti-aging therapies that can reverse tissue and organ degeneration. The company was founded on November 22, 2018 and is headquartered in Seongnam, South Korea. | Commercial Services |
CoImmune, Inc.
CoImmune, Inc. Pharmaceuticals: MajorHealth Technology CoImmune, Inc. engages in manufacture and development of cell-based therapeutics. It offers warehouse management, processing suites, logistics, research labs, and qualification and validation. The company was founded in February 2019 and is headquartered in Durham, NC. | Health Technology |
| Creactive Health Co. Ltd. |
- Stock Market
- Insiders
- Byeong-Geon Lee